Paloma Partners’s Immunic IMUX Stock Holding History

Paloma Partners’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-299	Closed	-$347K	–	2246
2017 Q2	$347K	Buy	+299	New	+$399K	﹤0.01%	1740
2017 Q1	–	Sell	-31	Closed	-$54K	–	2092
2016 Q4	$54K	Buy	+31	New	+$67.9K	﹤0.01%	1926

Other funds holding IMUX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Paloma Partners's IMUX Position: Q3 2017 in Review

Paloma Partners sold out of Immunic (IMUX) in Q3 2017, closing a stake of 299 shares — an estimated $347K sold.

Paloma Partners first reported a position in IMUX in Q4 2016 and held it in 2 quarters. The position peaked at $347K in Q2 2017. 42 funds tracked by Wall St. Rank hold IMUX as of Q3 2017.

Paloma Partners reported no remaining Immunic position as of Q3 2017 after selling out during the quarter.
Paloma Partners sold 299 Immunic shares in Q3 2017, an estimated $347K.
Paloma Partners first reported a position in Immunic in Q4 2016 and held it in 2 quarters.
Paloma Partners's Immunic position peaked at $347K in Q2 2017.
42 funds tracked by Wall St. Rank held Immunic as of Q3 2017.

Based on Paloma Partners's 13F filing for Q3 2017, filed 14 Nov 2017.